Appendix 4C and Quarterly Activity Report 31 March 2026
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report highlights positive cash flow and significant revenue growth in the Pain Management segment, particularly for Penthrox in both Australia and Europe. The company anticipates finalizing pediatric approvals for Penthrox in Europe and aims to enhance operational efficiencies moving forward. The report also notes a cash balance at the end of the quarter, reflecting the company's financial health and operational activities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Medical Developments International's latest callMedical Developments International (ASX:MVP) Q4 2026 Earnings Call · Replay · Aug 19Read the transcript of Medical Developments International (ASX:MVP) Q4 2026 Earnings CallMedical Developments International Limited on 6ix
Story so far
Earlier from Medical Developments International
- FY26 Half Year Presentation
- FY26 Half Year Announcement
- FY26 Half Year Report (including Appendix 4D)
- Appendix 4C and Quarterly Activity Report 31 December 2025
- Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO
Later from Medical Developments International
- Appendix 4C and Quarterly Activity Report 30 June 2026
- MVP Announces FY26 Full Year Results
- CEO Transition
- Appendix 4C and Quarterly Activity Report -30 September 2026
Follow Medical Developments International into a list and get an email when it puts out news.
Follow Medical Developments International